You are here: Industry Insights > Market News > Pharma firm to pay $1.3B fine for vaccine scandal

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Avatrombopag Maleate

BioHub® Magnetic Separator

Avatrombopag

Ursodeoxycholic acid

Troxerutin

CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Pharma firm to pay $1.3B fine for vaccine scandal

biospectrumasiaOctober 19, 2018

Tag: Vaccine , scandal

Favorites

Changchun Changsheng Life Sciences Ltd has been charged with a huge fine of $1.3 billion for falsifying production records in a scandal that prompted a nationwide crackdown on the vaccine industry.

Although no injuries were reported from use of Changsheng Life Science's rabies vaccines, authorities ordered a recall of its products from Chinese and foreign markets.

The pharma firm had used expired materials, mixed different batches of products and failed to test them properly. It was revealed that the company destroyed records to conceal its misconduct. 14 of its executives as well as its chairwoman were arrested while dozens were banned working in the drugs sector.

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.

Previous:PureTech affiliate Karuna advances schizophrenia candidate

Next:Robot addresses British MPs over future of AI

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Pharma firm to pay $1.3B fine for vaccine scandal | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Group ACYW135 Meningococcal Polysaccharide Vaccine with lower side effect by hualan biological

Hualan Biological H7N9 Inactivated Influenza Vaccine

Hualan Biological Flu Vaccine

Inactivated influenza vaccine

Influenza Vaccine(Split Virion),Inactivated of Hualan Bio

Eurping GMP Washing and Drying Instrument Applied to Pharmaceutical and Vaccine Production

Hualan Group ACYW135 Meningococcal Polysaccharide Vaccine with lower side effect and high quality

Hualan Biological inactivated flu vaccine

Group ACYW135 Meningococcal Polysaccharide Vaccine

2024-2025 quadrivalent/trivalent flu vaccine

Pharma firm to pay $1.3B fine for vaccine scandal

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may likeMore>>

You may like
More>>